MDT

88.01

+1.43%↑

A

119.52

+3.69%↑

VEEV

158.24

+2.16%↑

HQY

80.12

+2.21%↑

TLRY

7.02

+9.69%↑

MDT

88.01

+1.43%↑

A

119.52

+3.69%↑

VEEV

158.24

+2.16%↑

HQY

80.12

+2.21%↑

TLRY

7.02

+9.69%↑

MDT

88.01

+1.43%↑

A

119.52

+3.69%↑

VEEV

158.24

+2.16%↑

HQY

80.12

+2.21%↑

TLRY

7.02

+9.69%↑

MDT

88.01

+1.43%↑

A

119.52

+3.69%↑

VEEV

158.24

+2.16%↑

HQY

80.12

+2.21%↑

TLRY

7.02

+9.69%↑

MDT

88.01

+1.43%↑

A

119.52

+3.69%↑

VEEV

158.24

+2.16%↑

HQY

80.12

+2.21%↑

TLRY

7.02

+9.69%↑

Search

Stevanato Group SpA

Avatud

SektorTervishoid

14.26 6.42

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

13.5

Max

14.4

Põhinäitajad

By Trading Economics

Sissetulek

-2M

47M

Müük

40M

343M

P/E

Sektori keskmine

23.373

66.418

Kasumimarginaal

13.738

Töötajad

6,010

EBITDA

18M

90M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+81.21% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

7. mai 2026

Turustatistika

By TradingEconomics

Turukapital

-355M

3.8B

Eelmine avamishind

7.84

Eelmine sulgemishind

14.26

Uudiste sentiment

By Acuity

50%

50%

154 / 348 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Stevanato Group SpA Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

13. apr 2026, 23:25 UTC

Uudisväärsed sündmused

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy -- Update

13. apr 2026, 22:45 UTC

Uudisväärsed sündmused

Westpac Expects Higher Loan Losses as Iran Conflict Slows Australian Economy

13. apr 2026, 18:03 UTC

Tulu

Louis Vuitton Owner Logs Weak Sales as Middle East War Takes Toll -- 2nd Update

13. apr 2026, 23:58 UTC

Tulu

Review & Preview: Earnings Time -- Barrons.com

13. apr 2026, 23:49 UTC

Market Talk

Nikkei May Rise After Overnight Gains on Wall Street -- Market Talk

13. apr 2026, 23:33 UTC

Market Talk
Uudisväärsed sündmused

Gold Edges Higher Amid Dollar Weakness -- Market Talk

13. apr 2026, 23:20 UTC

Market Talk

Uranium Stocks Seen Benefiting From Energy Security Concerns -- Market Talk

13. apr 2026, 23:01 UTC

Tulu

Aura: Capex Guidance Revised From $111M and $130M to New Range of $262M and $314M >AURA33.SA.BR

13. apr 2026, 23:01 UTC

Tulu

Aura Minerals: Announces Update to Capex Guidance Including Construction of the Era Dorada Project

13. apr 2026, 23:01 UTC

Tulu

Aura: Will Update Cap Expenditure Guidance to Include the Project's Construction Phase >AURA33.SA.BR

13. apr 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Chevron Swaps Offshore Gas Stakes to Boost Venezuelan Heavy-Oil Footprint -- Update

13. apr 2026, 21:53 UTC

Tulu

MarketWise, Inc.: Affirms FY 2026 Guidance, Including Div Target to Class A Hldrs of $1.80 per Shr

13. apr 2026, 21:53 UTC

Tulu

MarketWise, Inc.: Paid Subscribers Were 381,000 at March 31 Compared to 374,000 at Dec 31, 2025, Active Free Subscribers Were 2.0M at March 31 >MKTW

13. apr 2026, 21:53 UTC

Tulu

MarketWise, Inc.: 1Q Billings Increased Approximately 15% Yr-over-Yr to Approximately $81M

13. apr 2026, 21:53 UTC

Tulu

MarketWise, Inc.: Preliminary Selected Unaudited 1Q Paid Subscribers Returning to Growth

13. apr 2026, 21:26 UTC

Uudisväärsed sündmused

U.S. Oil Blockade Is Set to Boost American Exports -- and Prices at the Pump -- WSJ

13. apr 2026, 21:23 UTC

Tulu

Johnson & Johnson Earnings: Oncology Powers Growth, but Talc Lawsuits Persist -- Barrons.com

13. apr 2026, 21:16 UTC

Tulu

Goldman Sachs Reports Record Quarter in Banking and Trading -- 4th Update

13. apr 2026, 20:50 UTC

Market Talk
Uudisväärsed sündmused

Basic Materials Roundup: Market Talk

13. apr 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

13. apr 2026, 20:34 UTC

Tulu

Victory Capital: 1Q Long-Term AUM Net Flows of -$457M >VCTR

13. apr 2026, 20:34 UTC

Tulu

Victory Capital: March Avg Total AUM Was $315.3B, Avg Other Assets $3.2B, Avg Total Client Assets $318.5B >VCTR

13. apr 2026, 20:34 UTC

Tulu

Victory Capital Holdings, Inc.: Total Assets Under Management of $309.8B, Other Assets $3.3B, Total Client Assets of $313.1B as of March 31 >VCTR

13. apr 2026, 19:59 UTC

Market Talk

Canada Consumers Sour Prior to Big Energy-Price Jump -- Market Talk

13. apr 2026, 19:50 UTC

Market Talk
Uudisväärsed sündmused

Oil Futures Pull Back From Highs on Hopes for Talks -- Market Talk

13. apr 2026, 19:27 UTC

Market Talk
Uudisväärsed sündmused

Correction to Precious Metals Market Talk on April 9

13. apr 2026, 19:14 UTC

Market Talk

U.S. Natural Gas Futures Settle Lower on Mild Weather -- Market Talk

13. apr 2026, 18:59 UTC

Market Talk
Uudisväärsed sündmused

Fed's Goolsbee: Don't Be Surprised If Consumer Confidence Sours -- Market Talk

13. apr 2026, 18:59 UTC

Market Talk
Uudisväärsed sündmused

Fed's Goolsbee: Oil Shows People Expect Short Term Conflict in Iran -- Market Talk

13. apr 2026, 18:43 UTC

Market Talk

Precious Metals Lose Ground as U.S. Blockade in Hormuz Gets Underway -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Stevanato Group SpA Prognoos

Hinnasiht

By TipRanks

81.21% tõus

12 kuu keskmine prognoos

Keskmine 24.5 USD  81.21%

Kõrge 32 USD

Madal 17.5 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Stevanato Group SpA 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

4

Osta

2

Hoia

0

Müü

Tehniline skoor

By Trading Central

21.56 / 22.61Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

154 / 348 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Keskmine

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Stevanato Group SpA

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.
help-icon Live chat